Patent ID: 8835425
Filing Date: 2014-09-16
Classification: A61K,A61P,C07D

Abstract:
1. A method of treating or delaying the progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the cortex and hippocampus comprising administering to a subject having such condition a therapeutically effective amount of a GABA A α5 negative allosteric modulator wherein the GABA A α5 negative allosteric modulator is (1,1-Dioxo-1,6-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone, or a pharmaceutically acceptable salt thereof, and wherein said CNS condition is cognitive deficits in Down Syndrome.